Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $55.33.

A number of analysts have recently issued reports on the company. Needham & Company LLC upgraded Establishment Labs from a "hold" rating to a "buy" rating and set a $48.00 price target for the company in a research report on Wednesday, May 14th. Stephens reiterated an "overweight" rating and set a $52.00 target price on shares of Establishment Labs in a research report on Thursday, March 6th. Wall Street Zen lowered shares of Establishment Labs from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, BTIG Research began coverage on shares of Establishment Labs in a report on Friday, May 16th. They set a "buy" rating and a $62.00 price objective for the company.

Establishment Labs Stock Performance

Shares of ESTA stock traded up $0.48 during trading on Tuesday, reaching $37.18. 398,942 shares of the company's stock traded hands, compared to its average volume of 476,085. The firm's 50-day moving average is $33.67 and its 200 day moving average is $37.55. The company has a market capitalization of $1.08 billion, a P/E ratio of -14.41 and a beta of 0.74. Establishment Labs has a 1 year low of $26.56 and a 1 year high of $58.00. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.13. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The company had revenue of $41.38 million during the quarter, compared to analysts' expectations of $41.15 million. During the same quarter in the previous year, the company earned ($0.58) earnings per share. Establishment Labs's revenue for the quarter was up 11.3% on a year-over-year basis. Equities research analysts expect that Establishment Labs will post -2.41 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

A number of large investors have recently added to or reduced their stakes in ESTA. Toronto Dominion Bank purchased a new stake in Establishment Labs during the fourth quarter valued at about $24,879,000. Brown Advisory Inc. boosted its holdings in Establishment Labs by 23.1% during the 4th quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock valued at $107,729,000 after acquiring an additional 438,057 shares during the period. Capital Research Global Investors grew its position in Establishment Labs by 29.3% during the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock worth $88,064,000 after acquiring an additional 433,484 shares during the last quarter. Voya Investment Management LLC increased its stake in shares of Establishment Labs by 7,249.5% in the fourth quarter. Voya Investment Management LLC now owns 408,262 shares of the company's stock worth $18,809,000 after buying an additional 402,707 shares during the period. Finally, Millennium Management LLC boosted its position in Establishment Labs by 96.9% during the 4th quarter. Millennium Management LLC now owns 711,691 shares of the company's stock valued at $32,788,000 after buying an additional 350,213 shares during the period. Hedge funds and other institutional investors own 72.91% of the company's stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.